CD49d is an independent prognostic marker that is associated with CXCR4 expression in CLL: Leuk Res

A. Majid; T. T. Lin; G. Best; K. Fishlock; S. Hewamana; G. Pratt; D. Yallop; A. G. Buggins; S. Wagner; B. J. Kennedy; F. Miall; R. Hills; S. Devereux; D. G. Oscier; M. J. Dyer; C. Fegan; C. Pepper

doi:10.1016/j.leukres.2010.10.022

CD49d is an independent prognostic marker that is associated with CXCR4 expression in CLL: Leuk Res

A. Majid, T. T. Lin, G. Best, K. Fishlock, S. Hewamana, G. Pratt, D. Yallop, A. G. Buggins, S. Wagner, B. J. Kennedy, F. Miall, R. Hills, S. Devereux, D. G. Oscier, M. J. Dyer, C. Fegan, C. Pepper

Research output: Contribution to journal › Article › peer-review

50 Citations (Scopus)

Abstract

The world of chronic lymphocytic leukemia (CLL) research is awash with prognostic markers. However, very few of the current group play a clearly defined role in the pathology of this disease and even fewer represent a tractable therapeutic target. One such marker that fulfils both of these criteria is the integrin CD49d. This molecule been implicated in the capacity of CLL cells to migrate into lymphoid tissues and there is a CD49d blocking antibody, Natalizumab, currently in clinical trials. Here we carried out the largest multi-centre evaluation of CD49d as a prognostic marker in 652 primary CLL samples. We confirm that CD49d is predictive for time to first treatment (P

Original language	English
Pages (from-to)	750-756
Number of pages	7
Journal	Leukemia Research
Volume	35
Issue number	6
DOIs	https://doi.org/10.1016/j.leukres.2010.10.022
Publication status	Published - Jun 2011
Externally published	Yes

Access to Document

10.1016/j.leukres.2010.10.022

Cite this

Majid, A., Lin, T. T., Best, G., Fishlock, K., Hewamana, S., Pratt, G., Yallop, D., Buggins, A. G., Wagner, S., Kennedy, B. J., Miall, F., Hills, R., Devereux, S., Oscier, D. G., Dyer, M. J., Fegan, C., & Pepper, C. (2011). CD49d is an independent prognostic marker that is associated with CXCR4 expression in CLL: Leuk Res. Leukemia Research, 35(6), 750-756. https://doi.org/10.1016/j.leukres.2010.10.022

Majid, A. ; Lin, T. T. ; Best, G. ; Fishlock, K. ; Hewamana, S. ; Pratt, G. ; Yallop, D. ; Buggins, A. G. ; Wagner, S. ; Kennedy, B. J. ; Miall, F. ; Hills, R. ; Devereux, S. ; Oscier, D. G. ; Dyer, M. J. ; Fegan, C. ; Pepper, C. / CD49d is an independent prognostic marker that is associated with CXCR4 expression in CLL : Leuk Res. In: Leukemia Research. 2011 ; Vol. 35, No. 6. pp. 750-756.

@article{ebf110f000414575a7042db1b8519cb8,

title = "CD49d is an independent prognostic marker that is associated with CXCR4 expression in CLL: Leuk Res",

abstract = "The world of chronic lymphocytic leukemia (CLL) research is awash with prognostic markers. However, very few of the current group play a clearly defined role in the pathology of this disease and even fewer represent a tractable therapeutic target. One such marker that fulfils both of these criteria is the integrin CD49d. This molecule been implicated in the capacity of CLL cells to migrate into lymphoid tissues and there is a CD49d blocking antibody, Natalizumab, currently in clinical trials. Here we carried out the largest multi-centre evaluation of CD49d as a prognostic marker in 652 primary CLL samples. We confirm that CD49d is predictive for time to first treatment (P",

author = "A. Majid and Lin, {T. T.} and G. Best and K. Fishlock and S. Hewamana and G. Pratt and D. Yallop and Buggins, {A. G.} and S. Wagner and Kennedy, {B. J.} and F. Miall and R. Hills and S. Devereux and Oscier, {D. G.} and Dyer, {M. J.} and C. Fegan and C. Pepper",

year = "2011",

month = jun,

doi = "10.1016/j.leukres.2010.10.022",

language = "English",

volume = "35",

pages = "750--756",

journal = "Leukemia Research",

issn = "0145-2126",

number = "6",

}

Majid, A, Lin, TT, Best, G, Fishlock, K, Hewamana, S, Pratt, G, Yallop, D, Buggins, AG, Wagner, S, Kennedy, BJ, Miall, F, Hills, R, Devereux, S, Oscier, DG, Dyer, MJ, Fegan, C & Pepper, C 2011, 'CD49d is an independent prognostic marker that is associated with CXCR4 expression in CLL: Leuk Res', Leukemia Research, vol. 35, no. 6, pp. 750-756. https://doi.org/10.1016/j.leukres.2010.10.022

CD49d is an independent prognostic marker that is associated with CXCR4 expression in CLL : Leuk Res. / Majid, A.; Lin, T. T.; Best, G.; Fishlock, K.; Hewamana, S.; Pratt, G.; Yallop, D.; Buggins, A. G.; Wagner, S.; Kennedy, B. J.; Miall, F.; Hills, R.; Devereux, S.; Oscier, D. G.; Dyer, M. J.; Fegan, C.; Pepper, C.

In: Leukemia Research, Vol. 35, No. 6, 06.2011, p. 750-756.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - CD49d is an independent prognostic marker that is associated with CXCR4 expression in CLL

T2 - Leuk Res

AU - Majid, A.

AU - Lin, T. T.

AU - Best, G.

AU - Fishlock, K.

AU - Hewamana, S.

AU - Pratt, G.

AU - Yallop, D.

AU - Buggins, A. G.

AU - Wagner, S.

AU - Kennedy, B. J.

AU - Miall, F.

AU - Hills, R.

AU - Devereux, S.

AU - Oscier, D. G.

AU - Dyer, M. J.

AU - Fegan, C.

AU - Pepper, C.

PY - 2011/6

Y1 - 2011/6

N2 - The world of chronic lymphocytic leukemia (CLL) research is awash with prognostic markers. However, very few of the current group play a clearly defined role in the pathology of this disease and even fewer represent a tractable therapeutic target. One such marker that fulfils both of these criteria is the integrin CD49d. This molecule been implicated in the capacity of CLL cells to migrate into lymphoid tissues and there is a CD49d blocking antibody, Natalizumab, currently in clinical trials. Here we carried out the largest multi-centre evaluation of CD49d as a prognostic marker in 652 primary CLL samples. We confirm that CD49d is predictive for time to first treatment (P

AB - The world of chronic lymphocytic leukemia (CLL) research is awash with prognostic markers. However, very few of the current group play a clearly defined role in the pathology of this disease and even fewer represent a tractable therapeutic target. One such marker that fulfils both of these criteria is the integrin CD49d. This molecule been implicated in the capacity of CLL cells to migrate into lymphoid tissues and there is a CD49d blocking antibody, Natalizumab, currently in clinical trials. Here we carried out the largest multi-centre evaluation of CD49d as a prognostic marker in 652 primary CLL samples. We confirm that CD49d is predictive for time to first treatment (P

U2 - 10.1016/j.leukres.2010.10.022

DO - 10.1016/j.leukres.2010.10.022

M3 - Article

VL - 35

SP - 750

EP - 756

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

IS - 6

ER -

CD49d is an independent prognostic marker that is associated with CXCR4 expression in CLL: Leuk Res

Abstract

Access to Document

Fingerprint

Cite this